| Year |
Citation |
Score |
| 2017 |
Kuo HP, Ezell SA, Schweighofer KJ, Cheung LW, Hsieh S, Apatira M, Sirisawad M, Eckert K, Hsu SJ, Chen CT, Beaupre DM, Versele M, Chang BY. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Molecular Cancer Therapeutics. PMID 28428442 DOI: 10.1158/1535-7163.Mct-16-0555 |
0.353 |
|
| 2016 |
Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, Davies BR, Huszar D, Byth KF. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. PMID 26824321 DOI: 10.18632/Oncotarget.7036 |
0.437 |
|
| 2015 |
Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S, D'Cruz CM. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. Oncotarget. 6: 2407-20. PMID 25537515 DOI: 10.18632/Oncotarget.2964 |
0.419 |
|
| 2014 |
Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer C, Byth KF. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. Oncotarget. 5: 4990-5001. PMID 24970801 DOI: 10.18632/Oncotarget.2071 |
0.394 |
|
| 2014 |
Kottakis F, Foltopoulou P, Sanidas I, Keller P, Wronski A, Dake BT, Ezell SA, Shen Z, Naber SP, Hinds PW, McNiel E, Kuperwasser C, Tsichlis PN. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. Cancer Research. 74: 3935-46. PMID 24853546 DOI: 10.1158/0008-5472.Can-13-2733 |
0.517 |
|
| 2014 |
Sourvinos G, Morou A, Sanidas I, Codruta I, Ezell SA, Doxaki C, Kampranis SC, Kottakis F, Tsichlis PN. The downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection. Plos Pathogens. 10: e1004136. PMID 24830456 DOI: 10.1371/Journal.Ppat.1004136 |
0.531 |
|
| 2014 |
Sanidas I, Polytarchou C, Hatziapostolou M, Ezell SA, Kottakis F, Hu L, Guo A, Xie J, Comb MJ, Iliopoulos D, Tsichlis PN. Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer. Molecular Cell. 53: 577-90. PMID 24462114 DOI: 10.1016/J.Molcel.2013.12.018 |
0.566 |
|
| 2014 |
Sourvinos G, Morou A, Sanidas I, Codruta I, Ezell SA, Doxaki C, Kampranis SC, Kottakis F, Tsichlis PN. NDY1/KDM2B, EZH2 and JARID2 are selectively required for the infection of human foreskin fibroblasts with HCMV whereas the H3K27me3 demethylase JMJD3 inhibits viral infection. Plos Pathogens. DOI: 10.1371/Journal.Ppat.1004136.G001 |
0.496 |
|
| 2014 |
Sanidas I, Polytarchou C, Hatziapostolou M, Ezell SA, Kottakis F, Hu L, Guo A, Xie J, Comb MJ, Iliopoulos D, Tsichlis PN. Abstract 4777: A phosphoproteomics analysis reveals Akt isoform-specific signals that link RNA splicing to non-small cell lung cancer Cancer Research. 74: 4777-4777. DOI: 10.1158/1538-7445.Am2014-4777 |
0.594 |
|
| 2013 |
Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. Acs Chemical Biology. 8: 2145-50. PMID 23899692 DOI: 10.1021/Cb400430T |
0.411 |
|
| 2012 |
Ezell SA, Tsichlis PN. Akt1, EMSY, BRCA2 and type I IFN signaling: a novel arm of the IFN response. Transcription. 3: 305-9. PMID 23117821 DOI: 10.4161/trns.21904 |
0.517 |
|
| 2012 |
Ezell SA, Polytarchou C, Hatziapostolou M, Guo A, Sanidas I, Bihani T, Comb MJ, Sourvinos G, Tsichlis PN. The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY. Proceedings of the National Academy of Sciences of the United States of America. 109: E613-21. PMID 22315412 DOI: 10.1073/Pnas.1115029109 |
0.61 |
|
| Show low-probability matches. |